Lexpos News

Ahead of 1st June 2025, pharmacy owners are reminded of the changes to the bundling requirements for Pharmacy First which will impact on whether they are entitled to a monthly fixed payment for the service. From 1st June 2025, pharmacy owners must be registered and able to deliver the Hypertension Case Finding Service*, the Pharmacy [...]

The post Reminder: Pharmacy First bundling requirement from 1st June appeared first on Community Pharmacy England.

Pharmacy owners have one week left to claim an Aspiration payment for the Pharmacy Quality Scheme (PQS) 2025/26 as the window for claiming this payment closes at 11.59pm on Friday 16th May 2025. The Aspiration payment is optional; if pharmacy owners do not want to claim it, it will not impact on the pharmacy owner’s [...]

The post PQS: One week left to claim the Aspiration payment appeared first on Community Pharmacy England.

Pharmacy owners should be aware that the Pharmacy First Clinical Pathways band assignments and monthly caps for May 2025 are published on the NHSBSA website. Information for all future months will be published here. The list published by NHSBSA indicates the band assignment and monthly cap for each pharmacy by ODS code. If a pharmacy [...]

The post Pharmacy First Clinical Pathways caps for May 2025 appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Chloramphenicol 1% w/w Eye Ointment, Blumont Pharma Limited Drug alert number: EL(25)A/20 Date issued: 08 May 2025 Blumont Pharma Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of the batch of Chloramphenicol 1% w/w Eye Ointment (POM version only) in [...]

The post MHRA Class 4 Medicines Defect Notification: Chloramphenicol 1% w/w Eye Ointment, Blumont Pharma Limited appeared first on Community Pharmacy England.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the risk of psychological side effects while taking Kaftrio▼ (Ivacaftor, tezacaftor, elexacaftor). Psychological side effects such as anxiety, low mood, sleep disturbance, poor concentration, and forgetfulness have been infrequently reported in people with cystic fibrosis treated with Kaftrio. Healthcare professionals should advise patients [...]

The post MHRA Drug Safety Update: Kaftrio▼ (Ivacaftor, tezacaftor, elexacaftor) risk of psychological side effects appeared first on Community Pharmacy England.